VIDEO: Nivolumab-chemotherapy shows advantage in younger and older patients with Hodgkin lymphoma
Click Here to Manage Email Alerts
In this video, Stephen M. Ansell, MD, PhD, discussed updated study results showing an advantage of nivolumab-chemo over brentuximab vedotin-chemo in both younger and older patients.
The studies, presented at ASH Annual Meeting and Exposition, evaluated patients between 12 and 18 years old and patients over the age of 60 with classic Hodgkin lymphoma. They examined a chemotherapy regimen of doxorubicin, vinblastine and dacarbazine (AVD) with either nivolumab (Opdivo, Bristol Myers Squibb) or brentuximab vedotin (Adcetris, Seagen).
"The interesting results were that in both cases there continues to be an advantage of nivolumab-AVD chemotherapy over the brentuximab AVD chemotherapy," Ansell, professor of medicine in the department of hematology at Mayo Clinic, Minnesota, said.
“There were slightly different take aways from each cohort,” Ansell said. “Younger patients tolerated all treatment really well. In the older patients, clearly the biggest benefit — and the benefit was quite substantial — was that nivolumab-AVD chemotherapy was much better tolerated than brentuximab AVD chemotherapy," Ansell said.
References:
- Castellino S, et al. Progression-free survival (PFS) and toxicity with nivolumab-AVD compared to brentuximab vedotin-AVD in pediatric advanced stage (AS) classic Hodgkin lymphoma (cHL), results of SWOG S1826. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
- Rutherford S, et al. Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged 60 Years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Click Here to Manage Email Alerts